Biological Activity
Obicetrapib, also known as TA-8995, is a CETP inhibitor for lipoprotein metabolism and cholesterol-efflux research. Published human study results are separated from preclinical assays below.
In Vitro
No separate compound-specific cell or biochemical result is available from the sources summarized here.
In Vivo
No compound-specific animal efficacy result is established by the sources summarized here.
Clinical / Human Evidence
| Endpoint | Model / conditions / source | Reported result |
|---|---|---|
| Study design | 187 participants with mild dyslipidemia; randomized treatment for 12 weeks. [1] | Compared placebo, TA-8995 1, 5 or 10 mg, and TA-8995 10 mg plus rosuvastatin 10 mg using serum lipoprotein and cholesterol-efflux endpoints. |
| Total cholesterol efflux | Participant serum tested in J774 macrophage-based assays; TA-8995 10 mg arm. [1] | Total cholesterol-efflux capacity increased by 38% relative to placebo. |
| Efflux pathways | Same 12-week study and dose arm. [1] | Non-ABCA1 and ABCA1-specific efflux capacities increased by 72% and 28%, respectively. |
| HDL remodeling | TA-8995 10 mg arm; serum HDL subclass analysis. [1] | Preβ-1 HDL increased by 36%; changes correlated with ABCA1-mediated efflux. These are biomarker outcomes, not cardiovascular event outcomes. |
Interpretation
These clinical biomarker results do not establish a cardiovascular-outcome benefit or describe the performance of a research reagent lot.
